Pete Pharma
A pharmaceutical innovation company that modernizes compounding through advanced 3D printing technology and proprietary delivery platforms for personalized solid drug dosage forms.
- CEO / Founder
- Daniel Siddall
- Team Size
- 1-10
- Stage
- Early Stage
Technology & Products
Key Products
3D printing platform for pharmaceuticals; Proprietary delivery platforms; Formulation development infrastructure
Technological Advantage
Partners with established pharmacy technology platforms (Atrium24) and major pharmaceutical distributors (Fagron) to embed its 3D printing technology into existing pharmacy workflows, creating a network effect and high switching costs. Its formulation expertise and IP are designed specifically for the compounding market.
Differentiation
Value Proposition
Enables on-demand, personalized medication production at the point-of-care, improving efficiency, compliance, and patient outcomes while reducing waste and inventory costs for pharmacies.
How They Differentiate
Unlike Aprecia (focused on FDA-approved mass-manufactured drugs) or FabRx (primarily a technology developer), Pete Pharma's model is built on exclusive distribution partnerships and integration into pharmacy purchasing groups (GPOs), aiming for rapid, scalable adoption within the existing independent pharmacy network.
Market & Competition
Target Customers
Compounding pharmacies, telehealth providers, independent pharmacies, and pharmaceutical distributors.
Industry Verticals
Pharmaceuticals; Healthcare; Compounding Pharmacy
Competitors
Aprecia Pharmaceuticals; FabRx; Merck KGaA (via partnership with AMCM)
Growth & Milestones
Growth Metrics
Partnerships: Formed partnership with Atrium24 Technologies, Inc. to bring 3D printing to independents; announced partnership with FABRx in September 2025 to bring pharmaceutical 3D printing to the USA; entered strategic partnership with Curexa to accelerate innovation in compounded therapies for the telehealth market. Acquisition interest: Embecta's acquisition of Owen Mumford noted Pete Pharma's formulation expertise, IP, and scalable product development infrastructure as contributing to revenue and margin growth.
Major Milestones
Strategic distribution partnership with Fagron (April 2026); Partnership with Atrium24 to bring 3D printing to independent pharmacies (March 2026); Partnership with Curexa for telehealth compounded therapies (January 2026); Partnership with FabRx to bring pharmaceutical 3D printing to US compounding pharmacies (September 2025)
Notable Customers
Independent pharmacies (via Atrium24 partnership), pharmaceutical compounding market, North American market via Fagron distribution